SCHEMBL25532173

SCHEMBL25532173

CCCCCC(C)N1C(=O)C=C(C(C)C)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
SHMT2 P34897 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP2C19 P33261 1/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PTGS1 P23219 3/20 0.33
PTGS2 P35354 3/20 0.33
MGLL Q99685 2/20 0.33
FAAH O00519 1/20 0.33
PTPN1 P18031 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
ACE2 Q9BYF1 1/20 0.31
OPRM1 P35372 1/20 0.31
POLB P06746 1/20 0.30
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23811151 0.81 SMN1; SMN2 (0.41) SMN1; SMN2LMNASHMT2ALDH1A1CYP2C19
SCHEMBL21114780 0.78 ACHE (0.41) SMN1; SMN2LMNASHMT2ALDH1A1CYP2C19
SCHEMBL3482787 0.75 MGLL (0.47) SMN1; SMN2LMNASHMT2ALDH1A1CYP2C19
SCHEMBL3482625 0.74 MGLL (0.50) SMN1; SMN2LMNASHMT2ALDH1A1CYP2C19
SCHEMBL12381793 0.73 EEF2K (0.35) PTPN1
SCHEMBL12132256 0.70 TDP1 (0.40) SMN1; SMN2LMNASHMT2ALDH1A1CYP2C19
SCHEMBL1535492 0.70 MGLL (0.44) SMN1; SMN2LMNASHMT2ALDH1A1CYP2C19
SCHEMBL29257418 0.69 TDP1 (0.54) LMNAALDH1A1PTPN1MEN1KMT2A
SCHEMBL30423475 0.69 TDP1 (0.54) LMNAALDH1A1PTPN1MEN1KMT2A
SCHEMBL12576925 0.69 STAT3 (0.42) SMN1; SMN2LMNASHMT2ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158169-A1 LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE AUDAX PRIVATE DEBT LLC, AS AGENT 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158169-A1 LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE CTSA, CTSS, CTSV SMN1; SMN2 763/4885LMNA 659/4885SHMT2 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.